1. Home
  2. PRFX vs ENVB Comparison

PRFX vs ENVB Comparison

Compare PRFX & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PainReform Ltd.

PRFX

PainReform Ltd.

HOLD

Current Price

$2.59

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Logo Enveric Biosciences Inc.

ENVB

Enveric Biosciences Inc.

HOLD

Current Price

$1.94

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRFX
ENVB
Founded
2007
1994
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7M
3.0M
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
PRFX
ENVB
Price
$2.59
$1.94
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$120.00
AVG Volume (30 Days)
209.2K
270.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$39,914,675.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.58
$0.56
52 Week High
$3.71
$13.25

Technical Indicators

Market Signals
Indicator
PRFX
ENVB
Relative Strength Index (RSI) 53.75 32.58
Support Level $1.28 $1.05
Resistance Level $3.65 $4.29
Average True Range (ATR) 0.31 0.19
MACD -0.12 0.05
Stochastic Oscillator 8.11 5.26

Price Performance

Historical Comparison
PRFX
ENVB

About PRFX PainReform Ltd.

PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.

About ENVB Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Share on Social Networks: